The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?
- Status
- COMPLETED
- Phase
- N/A
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Biweekly Docetaxel in Patients With Metastatic Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE3
Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
- Status
- COMPLETED
- Phase
- PHASE1
STAR Cape+BKM120 MBC With Brain Met
- Status
- COMPLETED
- Phase
- PHASE2
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- Status
- TERMINATED
- Phase
- PHASE2
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
- Status
- COMPLETED
- Phase
- PHASE2
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
- Status
- COMPLETED
- Phase
- PHASE3
AR and ER Imaging in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A